Relatlimab (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Relatlimab" in English language version.

refsWebsite

Global rank English rank

15nih.gov

4^th place

9doi.org

2^nd place

2ama-assn.org

3,257^th place

3,398^th place

1canada.ca

1,712^th place

1,063^rd place

1semanticscholar.org

11^th place

8^th place

1businesswire.com

615^th place

407^th place

1jhu.edu

699^th place

479^th place

1figshare.com

5,893^rd place

3,320^th place

1web.archive.org

1^st place

1handle.net

102^nd place

76^th place

ama-assn.org (Global: 3,257^th place; English: 3,398^th place)

searchusan.ama-assn.org

"Relatlimab". American Medical Association. Retrieved 22 March 2022.
Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab Archived 2018-09-24 at the Wayback Machine, American Medical Association.

businesswire.com (Global: 615^th place; English: 407^th place)

"U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma" (Press release). Bristol Myers Squibb. 18 March 2022. Retrieved 19 March 2022 – via Business Wire.

canada.ca (Global: 1,712^th place; English: 1,063^rd place)

"Notice: Multiple additions to the Prescription Drug List (PDL) [2023-12-22]". Health Canada. 22 December 2023. Retrieved 3 January 2024.

doi.org (Global: 2^nd place; English: 2^nd place)

Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DA (April 2019). "Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor". Seminars in Immunology. 42 101305. doi:10.1016/j.smim.2019.101305. PMC 6920665. PMID 31604537.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–264. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA (October 2004). "Role of LAG-3 in regulatory T cells". Immunity. 21 (4): 503–513. doi:10.1016/j.immuni.2004.08.010. PMID 15485628.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010). "Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates". Journal of Clinical Oncology. 28 (19): 3167–3175. doi:10.1200/JCO.2009.26.7609. PMC 4834717. PMID 20516446.
Gusmao EG, Allhoff M, Zenke M, Costa IG (April 2016). "Analysis of computational footprinting methods for DNase sequencing experiments". Nature Methods. 13 (4): 303–309. doi:10.1038/nmeth.3772. PMID 26901649.
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM (2018). "Neoadjuvant PD-1 blockade in resectable lung cancer". New England Journal of Medicine. 378 (21): 1976–1986. doi:10.1056/NEJMoa1716078. PMC 6223617. PMID 29658848.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski de Menezes J, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV (2022). "Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma". New England Journal of Medicine. 386 (1): 24–34. doi:10.1056/NEJMoa2109970. PMC 9844513. PMID 34986285.
Paik J (May 2022). "Nivolumab plus relatlimab: first approval". Drugs. 82 (8): 925–931. doi:10.1007/s40265-022-01723-1. PMID 35543970.

figshare.com (Global: 5,893^rd place; English: 3,320^th place)

Paik J (May 2022). "Nivolumab plus relatlimab: first approval". Drugs. 82 (8): 925–931. doi:10.1007/s40265-022-01723-1. PMID 35543970.

handle.net (Global: 102^nd place; English: 76^th place)

hdl.handle.net

"International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 81". WHO Drug Information. 33 (1). 2019. hdl:10665/330896.

jhu.edu (Global: 699^th place; English: 479^th place)

ventures.jhu.edu

Johns Hopkins Technology Ventures (December 2024). "10 Innovations in 10 Years: Relatlimab". John Hopkins Technological Ventures. Retrieved 23 January 2026.

nih.gov (Global: 4^th place; English: 4^th place)

pubmed.ncbi.nlm.nih.gov

Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.
Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DA (April 2019). "Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor". Seminars in Immunology. 42 101305. doi:10.1016/j.smim.2019.101305. PMC 6920665. PMID 31604537.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–264. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Huang CT, Workman CJ, Flies D, Pan X, Marson AL, Zhou G, Hipkiss EL, Ravi S, Kowalski J, Levitsky HI, Powell JD, Pardoll DM, Drake CG, Vignali DA (October 2004). "Role of LAG-3 in regulatory T cells". Immunity. 21 (4): 503–513. doi:10.1016/j.immuni.2004.08.010. PMID 15485628.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010). "Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates". Journal of Clinical Oncology. 28 (19): 3167–3175. doi:10.1200/JCO.2009.26.7609. PMC 4834717. PMID 20516446.
Gusmao EG, Allhoff M, Zenke M, Costa IG (April 2016). "Analysis of computational footprinting methods for DNase sequencing experiments". Nature Methods. 13 (4): 303–309. doi:10.1038/nmeth.3772. PMID 26901649.
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM (2018). "Neoadjuvant PD-1 blockade in resectable lung cancer". New England Journal of Medicine. 378 (21): 1976–1986. doi:10.1056/NEJMoa1716078. PMC 6223617. PMID 29658848.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski de Menezes J, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV (2022). "Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma". New England Journal of Medicine. 386 (1): 24–34. doi:10.1056/NEJMoa2109970. PMC 9844513. PMID 34986285.
Paik J (May 2022). "Nivolumab plus relatlimab: first approval". Drugs. 82 (8): 925–931. doi:10.1007/s40265-022-01723-1. PMID 35543970.

ncbi.nlm.nih.gov

Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DA (April 2019). "Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor". Seminars in Immunology. 42 101305. doi:10.1016/j.smim.2019.101305. PMC 6920665. PMID 31604537.
Pardoll DM (March 2012). "The blockade of immune checkpoints in cancer immunotherapy". Nature Reviews. Cancer. 12 (4): 252–264. doi:10.1038/nrc3239. PMC 4856023. PMID 22437870.
Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010). "Phase I study of single-agent anti–programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates". Journal of Clinical Oncology. 28 (19): 3167–3175. doi:10.1200/JCO.2009.26.7609. PMC 4834717. PMID 20516446.
Forde PM, Chaft JE, Smith KN, Anagnostou V, Cottrell TR, Hellmann MD, Zahurak M, Yang SC, Jones DR, Broderick S, Battafarano RJ, Velez MJ, Rekhtman N, Olah Z, Naidoo J, Marrone KA, Verde F, Guo H, Zhang J, Caushi JX, Chan HY, Sidhom JW, Scharpf RB, White J, Gabrielson E, Wang H, Rosner GL, Rusch V, Wolchok JD, Merghoub T, Taube JM, Velculescu VE, Topalian SL, Brahmer JR, Pardoll DM (2018). "Neoadjuvant PD-1 blockade in resectable lung cancer". New England Journal of Medicine. 378 (21): 1976–1986. doi:10.1056/NEJMoa1716078. PMC 6223617. PMID 29658848.
Tawbi HA, Schadendorf D, Lipson EJ, Ascierto PA, Matamala L, Castillo Gutiérrez E, Rutkowski P, Gogas HJ, Lao CD, Janoski de Menezes J, Dalle S, Arance A, Grob JJ, Srivastava S, Abaskharoun M, Hamilton M, Keidel S, Simonsen KL, Sobiesk AM, Li B, Hodi FS, Long GV (2022). "Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma". New England Journal of Medicine. 386 (1): 24–34. doi:10.1056/NEJMoa2109970. PMC 9844513. PMID 34986285.

dailymed.nlm.nih.gov

"Opdualag- nivolumab and relatlimab-rmbw injection". DailyMed. 18 March 2022. Retrieved 22 March 2022.

semanticscholar.org (Global: 11^th place; English: 8^th place)

api.semanticscholar.org

Robert C (December 2021). "LAG-3 and PD-1 blockade raises the bar for melanoma". Nature Cancer. 2 (12): 1251–3. doi:10.1038/s43018-021-00276-8. PMID 35121906. S2CID 245407697.

web.archive.org (Global: 1^st place; English: 1^st place)

Statement On A Nonproprietary Name Adopted By The USAN Council - Relatlimab Archived 2018-09-24 at the Wayback Machine, American Medical Association.

Relatlimab (English Wikipedia)

ama-assn.org (Global: 3,257th place; English: 3,398th place)

searchusan.ama-assn.org

businesswire.com (Global: 615th place; English: 407th place)

canada.ca (Global: 1,712th place; English: 1,063rd place)

doi.org (Global: 2nd place; English: 2nd place)

figshare.com (Global: 5,893rd place; English: 3,320th place)

handle.net (Global: 102nd place; English: 76th place)